Insofar as the lack of KRASmut druggable sites, the multifarity of downstream signaling pathways and the lack of a safe, efficient, and systemic tumor selective delivery vehicle have stymied the development of a translatable targeted treatment for KRAS mutated cancers, the bi-shRNAKRAS lipoplex, by addressing these obstacles, is primed for clinical implementation. Here, KRAS is linked to neoplasm.